Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
Authors:
Top Cited Papers
- 25 April 2022
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 21 (7) , 608-619
Abstract
No abstract availableKeywords
Funding Information
- Biogen
This publication has 29 references indexed in Scilit:
- Extended interval dosing of natalizumab in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2016
- Outcome and survival of asymptomatic PML in natalizumab‐treated MS patientsAnnals of Clinical and Translational Neurology, 2014
- Extended interval dosing of natalizumab: a two-center, 7-year experienceTherapeutic Advances in Neurological Disorders, 2014
- MS disease activity in RESTORENeurology, 2014
- MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trialsThe Lancet Neurology, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSNeurology, 2007
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MSExpert Review of Neurotherapeutics, 2004